15:30 , Jul 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal; autoimmune disease

INDICATION: Colitis; Crohn disease Mouse studies suggest inhibiting LRRK2 could help treat colitis and Crohn disease. In dendritic cells from eight Crohn patients, four LRRK2 inhibitor tool compounds decreased levels of inflammatory cytokines compared with vehicle....
18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
20:15 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Aivita raises $15M series B, considers Korean clinical trial for cancer therapy

Cellular therapy company Aivita Biomedical Inc. (Irvine, Calif.) raised $15 million on June 11 in a series B round led by sole South Korean investor SFC Co. Ltd. (KOSDAQ:112240). The round gives it a cash...
15:11 , Jun 8, 2018 |  BC Week In Review  |  Company News

Hookipa, Gilead partner to develop immunotherapies against HIV and HepB

Gilead Sciences Inc. (NASDAQ:GILD) gained exclusive, worldwide rights from Hookipa Biotech AG (Vienna, Austria) to use its TheraT and Vaxwave arenavirus-based vector technologies to develop immunotherapies for HBV and HIV infections. Hookipa is to receive $10...
01:36 , Jun 8, 2018 |  BC Innovations  |  Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
13:50 , Jun 5, 2018 |  BC Extra  |  Company News

Gilead, Hookipa in vector deal for HBV and HIV

Hookipa Biotech AG (Vienna, Austria) granted Gilead Sciences Inc. (NASDAQ:GILD) exclusive, worldwide rights to use its TheraT and Vaxwave arenavirus-based vector technologies to develop immunotherapies for HBV and HIV. Hookipa is to receive $10 million up...
19:22 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Sotio reports PFS data from Phase II of ovarian cancer immunotherapy

Sotio a.s. (Prague, Czech Republic) reported interim data from the Phase II SOV01 trial to treat epithelial ovarian carcinoma showing that first-line treatment with DCVAC/OvCa given sequentially after carboplatin and paclitaxel significantly improved median progression-free...
18:23 , May 25, 2018 |  BC Week In Review  |  Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and an...
15:04 , May 18, 2018 |  BC Extra  |  Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and an...
18:04 , May 11, 2018 |  BC Week In Review  |  Clinical News

Medigene reports Phase I/II data for prostate cancer vaccine

Medigene AG (Xetra:MDG1) said none of five high-risk prostate cancer patients who underwent radical surgery experienced biochemical relapse following vaccination with its DC vaccine targeting prostate-specific antigen (PSA; KLK3) that was generated with a toll-like...